Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune safety of a novel oncolytic mutant M1 after administration in vivo.

Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban - 1 Aug 2012

Jiang Lijun, Zhou Xiaoxi, Li Qinlu, Yu Fei, Huang Liang, Ma Quanfu, Zhou Jianfeng, Cao Yang

Abstract excerpt

The aim of this study was to evaluate the safety and efficiency of a novel, oncolytic adenovirus mutant M1 administered in conjunction with immunosuppressive agents. Animal models were established by administering purified M1 either intravenously or retroperitoneally. At different time points, blood samples were taken from the mice for testing of liver and renal function. Microscopic examination of the liver was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Kidney
Share to Adenoviridae

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mice, Inbred BALB C

Share to Mutation

Source

Identifiers

PMID: 22886963
DOI: 10.1007/s11596-012-0089-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune safety of a novel oncolytic mutant M1 after administration in vivo.PMID 22886963Read ↗

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacySemantic proximity Read ↗

Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.Semantic proximity Read ↗

Cancer Associated Endogenous Retroviruses: Ideal Immune Targets for Adenovirus-Based ImmunotherapySemantic proximity Read ↗

Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha.Semantic proximity Read ↗

Innate immunity to adenovirus: lessons from miceSemantic proximity Read ↗

A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse modelSemantic proximity Read ↗

Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?Semantic proximity Read ↗

The oncolytic virus ΔPK has multimodal anti-tumor activity.Semantic proximity Read ↗

Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and ChallengesSemantic proximity Read ↗

Parvoviruses NS1 oncolytic attributes: mechanistic insights and synergistic anti-tumor therapeutic strategiesSemantic proximity Read ↗

History of Oncolytic Viruses: Genesis to Genetic EngineeringSemantic proximity Read ↗

The Immune System – Friend or Foe for Adenovirus Based Therapies?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.